Clinical Trials Browser

Terminated × INDUSTRY × quizartinib × Clear all

NCT03552029 2022-05-20

Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML)

Phase 1 Terminated

10 enrolled 10 charts

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute